Takeda Boosts European, Emerging Markets Footprint With $13.6B Nycomed Buy
This article was originally published in The Pink Sheet Daily
Executive Summary
Japan's largest drug maker confirms Nycomed deal, which will double its European sales, jumpstart its emerging markets presence and provide a 30% revenue boost as key drug Actos faces patent expiry.